EyePoint Announces Topline Results from LUCIA, the Second Pivotal Phase 3 Clinical Trial of DURAVYU™ in Wet AMD
EyePoint announced that LUCIA, the second pivotal Phase 3 trial of DURAVYU in wet AMD, missed its primary endpoint of statistical non-inferiority in mean change in BCVA versus on-label aflibercept. Both Phase 3 trials (LUCIA, 475 patients; LUGANO, 432 patients) failed their primary endpoints despite meeting key secondaries, including a 38-42% reduction in treatment burden and >50% supplement-free rates at Week 56.
Key figures
- Drug Name
- DURAVYU (vorolanib intravitreal insert)
- Phase Of Trial
- Phase 3
- Dme topline data
- Q4 2027
- Lucia enrollment
- 475
- Lugano enrollment
- 432
- Lucia supplement free rate
- 52%
- Lucia treatment burden reduction
- 38%
- Lugano treatment burden reduction
- 42%
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.